Day 1 - Sunday, December 8, 2019
HEP DART 2019
Program Overview
Session 1: Global Viral Hepatitis and Chronic Liver Disease: Epidemiology and Prospects for Elimination -
Plenary Lecture: Current landscape of NASH, HCC and viral hepatitis
Robert Wong
Alameda Health Systems, USA
Controversies in chronic viral hepatitis epidemiology
Robert Gish
Hepatitis B Foundation, USA
Elimination of HCV in Egypt: A global model
SEARCHing for Hepatitis - the Australian conundrum
Miriam Levy
University of New South Wales, Australia
Highlights from the liver meeting, AASLD 2019
Michael Fried
University of North Carolina at Chapel Hill, USA
Update on ICE-HBV activities
Peter Revill
VIDRL, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Australia
Day 2 - Monday, December 9, 2019
-
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
William H. Prusoff HEP DART Lifetime Achievement Award lecture: On the origin of the hepatitis B virus: Will the real “Australia Antigen” please stand up?”
Victorian Infectious Diseases Reference Laboratory
Session 2: Overview of Viral Hepatitis and Nash -
State of the Art Lecture: Chronic hepatitis B viral infection in North America: Lessons from the hepatitis B research network
Adrian Di Bisceglie
Saint Louis University, USA
Colocation care model of HCV in people who inject drugs
Elana Rosenthal
University of Maryland, USA
Plenary Lecture: Mechanisms of NAFLD development and therapeutic strategies
Scott Friedman
Icahn School of Medicine at Mount Sinai, USA
Decoupling DAAs and HCC
Marc Bourlière
Hôpital Saint Joseph, France
Global Virus Network awareness
Christian Bréchot
University of South Florida, USA
Oral Abstract Session I: New Developments in Nucleoside and Nucleic Acid Ploymer Inhibitors of HBV -
A novel long-acting Anti-HBV nucleoside, E-CFCP, potently blocks the infectivity and replication of wild-type and drug-resistant HBVs in human-liver-chimeric mice with potential QW oral dosing schedule capabilities
Hiroaki Mitsuya
National Center for Global Health & Medicine/National Cancer Institute, Japan/ USA
ATI-2173, a novel HBV nucleoside phosphoramidate for HBV cure regimens
Douglas Mayers
Antios Therapeutics, USA
Transaminase flares during HBsAg reduction to < 1 IU/mL are correlated with the establishment of functional cure of HBV following NAP-based combination therapy
Andrew Vaillant
Replicor Inc., Canada
Session 3: Hepatitis B Basic Science (Hepatitis B Foundation Sponsored Session) -
Session 3: Hepatitis B Basic Science (Hepatitis B Foundation Sponsored Session)
Ju-tao Guo
Baruch S. Blumberg Institute of Living Science, USA
Single hepatocyte molecular analysis of HBV from paired biopsies in HIV-HBV co-infection
Chloe Thio
Johns Hopkins, USA
PD-1 blockade recovers dysfunctional virus-specific B cells in chronic hepatitis B infection
Antonio Bertoletti
Duke-NUS Medical School, Singapore
Occult HBV infection
Teresa Pollicino
University Hospital of Messina, Italy
Therapeutic vaccination in hepatitis B
Ulrike Protzer
Institute of Virology, Technical University of Munich, Germany
Session 4: Betting on a HEP B Cure -
Harry Janssen, MD, PhD
State of the art lecture: Clinical update on drugs for HBV Cure
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Plenary Lecture: What would an HBV cure look like? Endpoints and clinical trial design towards a cure
Anna Lok
University of Michigan, USA
Five decades of HBV research
George Lau
Humanity and Health Medical Group, Hong Kong
Oral Abstract Session II: New Therapeutic Interventions With Curative Potential For HBV -
Small molecule targeting of cis-acting regulatory RNAs encoded by Hepatitis B virus pre-genomic RNA and their therapeutic potential
Stuart Le Grice
National Cancer Institute, USA
A genome-wide CRISPR screen identifies ZCCHC14 as a host factor required for hepatitis B surface antigen production
Anastasia Hyrina
Novartis Institutes for BioMedical Research, USA
Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation
Lei Wei
Princeton University, USA
Day 3 - Tuesday, December 10, 2019
Session 5: Improvements on Current HBV, HCV, and HCC Therapy -
HBV in the Hepather cohort: Are all patients treated according to guideline and is there a place for improvement with the new regimen?
Marc Bourlière
Hôpital Saint Joseph, France
Modeling HBV therapies under development
Alan Perelson
Los Alamos National Laboratory, USA
HBV co-infection with HIV or HCV
Mark Sulkowski
Johns Hopkins University, USA
Plenary talk: Dash for NASH cure
Eduardo Martins
Allergan, USA
Session 6: Academic/Industry Session: Advances in Therapeutics for NASH/NAFLD -
Plenary Lecture: Human cell-based model systems combined with single cell RNASeq for discovery of novel liver disease therapeutics
Thomas Baumert
University of Strasbourg, France
Resmetirom (MGL-3196) for the treatment of nonalcoholic fatty liver disease (NAFLD): NASH fibrosis and NAFLD with dyslipidemia
Becky Taub
Madrigal Pharmaceuticals, USA
Combination therapy for NASH
Rob Myers
Gilead Sciences, USA
Aramchol, a stearoyl CoA desaturase (SCD1) modulator: From Scientific Rationale to a Phase 3/4 Clinical Trial for NASH and Fibrosis
Carol L. Brosgart
University of California San Francisco, USA
Session 7: Academic/Industry Session on Advances in Therapeutics for HBV -
Plenary Lecture: Eliminating residual HBV replication – A critical gateway to cure
Richard Colonno
Assembly Biosciences, USA
Where will RNAi fit in the era of finite therapies?
Bruce Given
Arrowhead Pharmaceuticals, USA
Progress toward an HBV cure combination therapy
Michael Sofia
Arbutus Biopharma, USA
Combination approaches towards a functional cure for chronic hepatitis B
Larry Blatt
Aligos Therapeutics, USA
A gene editing approach to eliminate hepatitis B virus in vivo with an ARCUS meganuclease evolved to prevent off target cutting
Amy Rhoden Smith
Precision Biosciences, USA
Overview of Janssen’s novel combination antiviral therapies towards achieving functional cure (FC) for chronic hepatitis B (CHB)
Heather Davis
Janssen, Belgium
Preclinical profile of a novel, potent core inhibitor, EDP-514
Eoin Coakley
Enanta Pharmaceuticals, USA
Day 4 - Wednesday December 11, 2019
Session 8: Immunity, Vaccines and Transplantation in the Context of HBV and HCV Infection -
Norah Terrault, MD, MPH, FAASLD
State of the Art Lecture: HBV vaccines new and old
Lessons learned from HCV vaccine testing
Andrea Cox
Johns Hopkins University, USA
Antiviral therapies for HBV and HCV infection in the context of liver transplantation
Michael Manns
Hannover Medical School, Germany
Transplantation of HCV-Viremic donors into HCV-negative recipients: Conquests and cautions
Keck School of Medicine of University of Southern California, Los Angelas, United States
Oral Abstract Session III: Advances in HCV Control and Elimination -
C19orf66 is an interferon-induced inhibitor of HCV replication restricting formation of the viral replication organelle
Kinast Volker
Ruhr University Bochum, Germany
Micro-elimination of hepatitis C among people with HIV coinfection: Decreasing incidence and prevalence following a treatment scale up program
Joseph Doyle
Monash University and Burnet Institute, Australia
Session 9: New Developments in Liver Disease, Firbrosis and NASH -
NASH therapeutics in children
Saul Karpen
Emory University, USA
Hepatic stellate cell phenotypes in NASH
David Brenner
University of California San Diego, USA
NAFLD and the heart
Laurence Sperling
Emory University, USA
Session 10: Illuminating New Approaches to Chronic Liver Disease -
State of the Art Lecture: From liver disease to HCC - All roads lead to Rome
Jake Liang
National Institutes of Health, USA
Genetic profiling and personalized medicine in HCC
Lewis Roberts
Mayo Clinic, USA
Discovery of protein signatures of NAFLD, NASH and HCC
Steve Williams
SomaLogic, USA
Viral hepatitis as a systemic disease: Extra-hepatic manifestations
Tarik Asselah
University Paris Diderot, INSERM, France
Oral Abstract Session IV: Clinical Trails and Animal Models for Fibrosis and Chronic Liver Disease -
Efficacy and safety of BMS-986263, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in patients with advanced hepatic fibrosis: Part 1 week 12 - results from a phase 2 randomized, double-blind, placebo-controlled trial
Eric Lawitz
Texas Liver Institute, USA
Role of integrin αVß6 expressed in damaged epithelium in fibrotic diseases primary sclerosing cholangitis and idiopathic pulmonary fibrosis: Common expression patterns in human disease and mouse models
Adrian Ray
Morphic Therapeutic, USA
Day 5 - Thursday, December 12, 2019
Session 11: Non-B, Non-C Viral Hepatitis: Epidemiology, Pathogenesis and Treatment -
State of the Art lecture: HDV epidemiology, pathogenesis, diagnosis and new treatments
Stephan Urban
Deutsches Zentrum für Infektionsforschung, Germany
Lonafarnib and Peginterferon Lambda: First-in-Class Drugs for HDV Infection
Jeffrey Glenn
Stanford University School of Medicine, and Eiger BioPharmaceuticals, Inc., USA
State of the Art lecture: Hepatitis A pathogenesis
Stanley Lemon
University of North Carolina at Chapel Hill, USA
HEV as a global disease: From epidemiology to cure
Kenneth Sherman
University of Cincinnati, USA
Oral Abstract Session V: New Findings in Virus Replication and Antiviral Strategies -
Hepatitis Delta Virus (HDV) histone mimicry drives the recruitment of cellular BRF chromatin remodelers for viral RNA replication
Massimo Levrero
INSERM, France
Towards a novel RNAi- and AAV vector-based gene therapy against hepatitis E virus
Cindy Zhang
Heidelberg University Hospital - Infectious Diseases, Germany
Local stabilization of protein subunit contacts causes global destabilization of hepatitis B virus capsids
Adam Zlotnick
Indiana University, USA
Key findings leading to the discontinuation of a capsid Inhibitor (CI), AB-506, in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Gaston Picchio
Arbutus Biopharma, USA
Does the galnac liver targeting of antisense oligonucleotides deliver improved clinical efficacy in patients with chronic hepatitis B: A cross study comparison
Dickens Theodore
GlaxoSmithKline, USA
2019 & Beyond: Looking to the horizon
Scott Friedman
Icahn School of Medicine at Mount Sinai, USA
Overview
Welcome
Dear Colleagues,
The focus of HEP DART is to assemble clinicians, medical professionals, nurses, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of viral hepatitis, NASH, and co-infections. HEP DART 2019 uniquely blended the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in hepatology (including viral hepatitis, NASH, and co-infections). Key points of the meeting were basic science and clinical medicine.
The program included plenary lectures, abstract and poster presentations, along with discussion & debate. There was plenty of time for Q&A in the panel discussions scheduled at the end of each session and more than enough occasions to unwind, relax and socialize with colleagues.
Program Chair,
Raymond F. Schinazi, PhD, DSc
Emory University, USA
Committees
Scientific Committee
- Harvey Alter — NIH, USA
- Ralf Bartenschlager — University of Heidelberg, Germany
- Mithat Bozdayi — Ankara University, Turkey
- Francis Chisari —The Scripps Research Institute
- Adrian Di Bisceglie — Saint Louis University, USA
- Geoffrey Dusheiko — University College London, UK
- Michael Fried — University of North Carolina, USA
- Robert Gish — Robert G. Gish Consultants, LLC, USA
- Jason Grebely — University of New South Wales, Australia
- Allison Jilbert — University of Adelaide, Australia
- Harry Janssen — Toronto General Hospital Research Institute, Canada
- Brent Korba — Georgetown University, USA
- Shyamasundaran Kottilil — Maryland University, USA
- George Lau — Humanity and Health Medical Center, Hong Kong, China
- Stanley Lemon —University of North Carolina at Chapel Hill, USA
- Miriam Levy — University of Western Sydney and University of New South Wales, Australia
- Anna Lok — University of Michigan Medical Center, USA
- Michael Manns — Hannover Medical School, Germany
- Patrick Marcellin — Hopital Beaujon, France
- John McHutchison — Gilead Sciences, Inc., USA
- Marion Peters — University of California, San Francisco, USA
- Tracy Swan — Treatment Action Group, USA
Support
Platinum Level
Gold Level
Sliver Level
Bronze Level
Blatt Family Foundation
